Details of the Drug Combination

General Information of Drug Combination (ID: DC9PHQO)

• Drug Combination Name: Vinblastine + Lapatinib
• Indication: Amelanotic melanoma; Status: Investigative [1]
• Component Drugs:
  Vinblastine (DM5TVS3): Small molecular drug
  Lapatinib (DM3BH1Y): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: A2058
  Zero Interaction Potency (ZIP) Score: 1.9
  Bliss Independence Score: 3.4
  Loewe Additivity Score: 1.01
  LHighest Single Agent (HSA) Score: 4.5

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Vinblastine

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[2]
Anterior urethra cancer	N.A.	Approved	[2]
Extragonadal germ cell tumor	N.A.	Approved	[2]
Gestational trophoblastic neoplasia	2F33-2F76	Approved	[2]
Kaposi sarcoma	2B57	Approved	[2]
Mycosis fungoides	2B01	Approved	[2]
Posterior urethra cancer	N.A.	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Testicular cancer	2C80	Approved	[2]
Testicular germ cell tumor	N.A.	Approved	[2]
Classic Hodgkin lymphoma	N.A.	Investigative	[2]

Vinblastine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tubulin beta-2 chain (TUBB2)	TTJ2PTI	TBB2A_HUMAN	Inhibitor	[7]

Vinblastine Interacts with 5 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[8]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[9]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[11]
Multidrug resistance protein 3 (ABCB4)	DTZRMK5	MDR3_HUMAN	Substrate	[12]

Vinblastine Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[13]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[14]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[15]

Vinblastine Interacts with 201 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Response To Substance	[16]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Response To Substance	[17]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Affects Transport	[18]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[19]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	OT9RDS3H	IKKB_HUMAN	Increases Phosphorylation	[20]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[21]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Expression	[22]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases Stability	[23]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[24]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Phosphorylation	[25]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Stability	[23]
Integrin alpha-L (ITGAL)	OTCUQAIS	ITAL_HUMAN	Decreases Expression	[24]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Increases Phosphorylation	[20]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Increases Phosphorylation	[25]
Mitogen-activated protein kinase 9 (MAPK9)	OTCEVJ9E	MK09_HUMAN	Increases Phosphorylation	[25]
Tumor necrosis factor ligand superfamily member 6 (FASLG)	OTZARCHH	TNFL6_HUMAN	Increases Expression	[26]
Protein kinase C delta type (PRKCD)	OTSEH90E	KPCD_HUMAN	Affects Localization	[22]
Nuclear factor of activated T-cells, cytoplasmic 4 (NFATC4)	OTTDCUAO	NFAC4_HUMAN	Decreases Localization	[27]
Transcriptional regulator QRICH1 (QRICH1)	OTPVAX04	QRIC1_HUMAN	Increases Phosphorylation	[28]
Sorting nexin-10 (SNX10)	OT05B7BT	SNX10_HUMAN	Affects Response To Substance	[6]
Histone H1.2 (H1-2)	OT0AVI4M	H12_HUMAN	Affects Response To Substance	[6]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Affects Response To Substance	[6]
Friend leukemia integration 1 transcription factor (FLI1)	OT0EV3LX	FLI1_HUMAN	Affects Response To Substance	[6]
Sulfotransferase 1A1 (SULT1A1)	OT0K7JIE	ST1A1_HUMAN	Affects Response To Substance	[6]
Histone H3-like centromeric protein A (CENPA)	OT0NEJ4X	CENPA_HUMAN	Affects Response To Substance	[6]
DNA polymerase zeta catalytic subunit (REV3L)	OT0OP8EJ	REV3L_HUMAN	Affects Response To Substance	[6]
Rab11 family-interacting protein 1 (RAB11FIP1)	OT0T71OW	RFIP1_HUMAN	Affects Response To Substance	[6]
Oxysterol-binding protein-related protein 10 (OSBPL10)	OT0TFMBE	OSB10_HUMAN	Affects Response To Substance	[6]
DNA-binding protein inhibitor ID-2 (ID2)	OT0U1D53	ID2_HUMAN	Affects Response To Substance	[6]
NADH dehydrogenase 1 alpha subcomplex subunit 13 (NDUFA13)	OT0UOKIT	NDUAD_HUMAN	Affects Response To Substance	[6]
Tripartite motif-containing protein 2 (TRIM2)	OT0V1YVC	TRIM2_HUMAN	Affects Response To Substance	[6]
Lamin-B1 (LMNB1)	OT100T3P	LMNB1_HUMAN	Affects Response To Substance	[6]
Borealin (CDCA8)	OT17D55D	BOREA_HUMAN	Affects Response To Substance	[6]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Increases Response To Substance	[29]
Condensin complex subunit 3 (NCAPG)	OT1AI9EO	CND3_HUMAN	Affects Response To Substance	[6]
m7GpppX diphosphatase (DCPS)	OT1FZVC9	DCPS_HUMAN	Affects Response To Substance	[6]
KN motif and ankyrin repeat domain-containing protein 1 (KANK1)	OT2E7A6W	KANK1_HUMAN	Affects Response To Substance	[6]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Affects Response To Substance	[6]
U11/U12 small nuclear ribonucleoprotein 25 kDa protein (SNRNP25)	OT2MR6O2	SNR25_HUMAN	Affects Response To Substance	[6]
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB)	OT2NHE5E	ODPB_HUMAN	Affects Response To Substance	[6]
N-acetylglucosamine-1-phosphotransferase subunits alpha/beta (GNPTAB)	OT2Z03OB	GNPTA_HUMAN	Affects Response To Substance	[6]
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Affects Response To Substance	[6]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Affects Response To Substance	[6]
Chromosome-associated kinesin KIF4A (KIF4A)	OT3UWL7D	KIF4A_HUMAN	Affects Response To Substance	[6]
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial (NDUFB2)	OT4717TF	NDUB2_HUMAN	Affects Response To Substance	[6]
High mobility group protein B1 (HMGB1)	OT4B7CPF	HMGB1_HUMAN	Affects Response To Substance	[6]
c-Myc-binding protein (MYCBP)	OT4IZR4R	MYCBP_HUMAN	Affects Response To Substance	[6]
Hyaluronan mediated motility receptor (HMMR)	OT4M0JTZ	HMMR_HUMAN	Affects Response To Substance	[6]
Transcription termination factor 2 (TTF2)	OT5LJOWM	TTF2_HUMAN	Affects Response To Substance	[6]
Neprilysin (MME)	OT5Q39P8	NEP_HUMAN	Affects Response To Substance	[6]
Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP1A)	OT6285L4	FKB1A_HUMAN	Affects Response To Substance	[6]
DNA topoisomerase 2-alpha (TOP2A)	OT6LPS08	TOP2A_HUMAN	Affects Response To Substance	[6]
Electron transfer flavoprotein subunit beta (ETFB)	OT6Q6FBD	ETFB_HUMAN	Affects Response To Substance	[6]
Flap endonuclease 1 (FEN1)	OT6QGG7O	FEN1_HUMAN	Affects Response To Substance	[6]
G-protein-signaling modulator 2 (GPSM2)	OT6RPMRM	GPSM2_HUMAN	Affects Response To Substance	[6]
Plasminogen activator inhibitor 2 (SERPINB2)	OT72QLZB	PAI2_HUMAN	Affects Response To Substance	[6]
CD40 ligand (CD40LG)	OT75Z6A6	CD40L_HUMAN	Decreases Response To Substance	[30]
Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1)	OT80DZMT	BUB1_HUMAN	Affects Response To Substance	[6]
Nucleolar and spindle-associated protein 1 (NUSAP1)	OT85HIJ5	NUSAP_HUMAN	Affects Response To Substance	[6]
Stanniocalcin-2 (STC2)	OT86YP8G	STC2_HUMAN	Affects Response To Substance	[6]
Pirin (PIR)	OT8ALXHU	PIR_HUMAN	Affects Response To Substance	[6]
NADH dehydrogenase 1 alpha subcomplex subunit 7 (NDUFA7)	OT8CV3H5	NDUA7_HUMAN	Affects Response To Substance	[6]
G0/G1 switch protein 2 (G0S2)	OT8FL49L	G0S2_HUMAN	Affects Response To Substance	[6]
Replication protein A 14 kDa subunit (RPA3)	OT8JAQGL	RFA3_HUMAN	Affects Response To Substance	[6]
Deoxyribose-phosphate aldolase (DERA)	OT8SMO3N	DEOC_HUMAN	Affects Response To Substance	[6]
NADH dehydrogenase iron-sulfur protein 6, mitochondrial (NDUFS6)	OT9IOONQ	NDUS6_HUMAN	Affects Response To Substance	[6]
NADH dehydrogenase 1 subunit C2 (NDUFC2)	OT9M119L	NDUC2_HUMAN	Affects Response To Substance	[6]
Beta-glucuronidase (GUSB)	OT9N1DK3	BGLR_HUMAN	Affects Response To Substance	[6]
Fos-related antigen 1 (FOSL1)	OT9YTYMB	FOSL1_HUMAN	Affects Response To Substance	[6]
High mobility group nucleosome-binding domain-containing protein 3 (HMGN3)	OTA2TBWS	HMGN3_HUMAN	Affects Response To Substance	[6]
Diphosphoinositol polyphosphate phosphohydrolase NUDT4B (NUDT4)	OTA6ICI2	NUD4B_HUMAN	Affects Response To Substance	[6]
Cysteine-rich PDZ-binding protein (CRIPT)	OTA6M8M4	CRIPT_HUMAN	Affects Response To Substance	[6]
Replication factor C subunit 5 (RFC5)	OTAD79RT	RFC5_HUMAN	Affects Response To Substance	[6]
ATP synthase subunit e, mitochondrial (ATP5ME)	OTADVEE2	ATP5I_HUMAN	Affects Response To Substance	[6]
Transmembrane protein 14A (TMEM14A)	OTANQA6G	TM14A_HUMAN	Affects Response To Substance	[6]
MAP kinase-activated protein kinase 5 (MAPKAPK5)	OTAZHPVK	MAPK5_HUMAN	Affects Response To Substance	[6]
Shootin-1 (SHTN1)	OTB07MOG	SHOT1_HUMAN	Affects Response To Substance	[6]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Affects Response To Substance	[6]
Fibronectin (FN1)	OTB5ZN4Q	FINC_HUMAN	Affects Response To Substance	[6]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)	OTB97VIK	IF2B3_HUMAN	Affects Response To Substance	[6]
Membrane-associated progesterone receptor component 1 (PGRMC1)	OTBE6WAC	PGRC1_HUMAN	Affects Response To Substance	[6]
Probable ATP-dependent RNA helicase DDX23 (DDX23)	OTBJHS8C	DDX23_HUMAN	Affects Response To Substance	[6]
Protein FAM3C (FAM3C)	OTBR6U9G	FAM3C_HUMAN	Affects Response To Substance	[6]
Transmembrane protein 134 (TMEM134)	OTBX9H9D	TM134_HUMAN	Affects Response To Substance	[6]
Dual specificity protein kinase TTK (TTK)	OTBY1Z5H	TTK_HUMAN	Affects Response To Substance	[6]
CCN family member 2 (CCN2)	OTC39NSU	CCN2_HUMAN	Affects Response To Substance	[6]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C)	OTCLOV90	CDN2C_HUMAN	Affects Response To Substance	[6]
Cytoskeleton-associated protein 2 (CKAP2)	OTCLTC0J	CKAP2_HUMAN	Affects Response To Substance	[6]
Cytochrome c oxidase copper chaperone (COX17)	OTCP4LH2	COX17_HUMAN	Affects Response To Substance	[6]
Tetraspanin-13 (TSPAN13)	OTCS9BZY	TSN13_HUMAN	Affects Response To Substance	[6]
S-phase kinase-associated protein 2 (SKP2)	OTD5B41X	SKP2_HUMAN	Affects Response To Substance	[6]
Succinate--CoA ligase subunit alpha, mitochondrial (SUCLG1)	OTDCSPXH	SUCA_HUMAN	Affects Response To Substance	[6]
Proteasome activator complex subunit 4 (PSME4)	OTDGF53O	PSME4_HUMAN	Affects Response To Substance	[6]
Gamma-adducin (ADD3)	OTDRSHAZ	ADDG_HUMAN	Affects Response To Substance	[6]
Superkiller complex protein 8 (SKIC8)	OTDSQYDN	SKI8_HUMAN	Affects Response To Substance	[6]
Dickkopf-related protein 3 (DKK3)	OTDU94EY	DKK3_HUMAN	Affects Response To Substance	[6]
Geminin (GMNN)	OTDYKNIY	GEMI_HUMAN	Affects Response To Substance	[6]
EF-hand calcium-binding domain-containing protein 7 (EFCAB7)	OTE0EG10	EFCB7_HUMAN	Affects Response To Substance	[6]
Vitamin K-dependent gamma-carboxylase (GGCX)	OTE0FNAP	VKGC_HUMAN	Affects Response To Substance	[6]
ATP synthase subunit f, mitochondrial (ATP5MF)	OTE4TBG9	ATPK_HUMAN	Affects Response To Substance	[6]
Maternal embryonic leucine zipper kinase (MELK)	OTEY2UQA	MELK_HUMAN	Affects Response To Substance	[6]
Protein pelota homolog (PELO)	OTF3WLIM	PELO_HUMAN	Affects Response To Substance	[6]
Serglycin (SRGN)	OTFAVSX0	SRGN_HUMAN	Affects Response To Substance	[6]
Sortilin (SORT1)	OTFCQ4B1	SORT_HUMAN	Affects Response To Substance	[6]
Exosome complex component RRP45 (EXOSC9)	OTFKB37F	EXOS9_HUMAN	Affects Response To Substance	[6]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Affects Response To Substance	[6]
High mobility group protein B2 (HMGB2)	OTGEGAOK	HMGB2_HUMAN	Affects Response To Substance	[6]
Phospholipid-transporting ATPase ABCA3 (ABCA3)	OTH6MSKQ	ABCA3_HUMAN	Decreases Response To Substance	[31]
Sigma intracellular receptor 2 (TMEM97)	OTH76ZWK	SGMR2_HUMAN	Affects Response To Substance	[6]
Transmembrane protein 156 (TMEM156)	OTH7YJID	TM156_HUMAN	Affects Response To Substance	[6]
Epithelial cell adhesion molecule (EPCAM)	OTHBZK5X	EPCAM_HUMAN	Affects Response To Substance	[6]
Protein regulator of cytokinesis 1 (PRC1)	OTHD0XS0	PRC1_HUMAN	Affects Response To Substance	[6]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Affects Response To Substance	[6]
Kinesin-like protein KIF11 (KIF11)	OTHRGLCQ	KIF11_HUMAN	Affects Response To Substance	[6]
Actin-binding LIM protein 1 (ABLIM1)	OTHXEK3E	ABLM1_HUMAN	Affects Response To Substance	[6]
U6 snRNA-associated Sm-like protein LSm7 (LSM7)	OTHZ2XPX	LSM7_HUMAN	Affects Response To Substance	[6]
Kinesin-like protein KIF1B (KIF1B)	OTI1XQTO	KIF1B_HUMAN	Affects Response To Substance	[6]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Affects Response To Substance	[6]
Protein Mis18-beta (OIP5)	OTI5C2DE	MS18B_HUMAN	Affects Response To Substance	[6]
G2/mitotic-specific cyclin-B2 (CCNB2)	OTIEXTDK	CCNB2_HUMAN	Affects Response To Substance	[6]
Securin (PTTG1)	OTIMYS4W	PTTG1_HUMAN	Affects Response To Substance	[6]
Baculoviral IAP repeat-containing protein 7 (BIRC7)	OTITCGHB	BIRC7_HUMAN	Decreases Response To Substance	[32]
Aurora kinase B (AURKB)	OTIY4VHU	AURKB_HUMAN	Affects Response To Substance	[6]
NADH dehydrogenase 1 subunit C1, mitochondrial (NDUFC1)	OTJ5TNHB	NDUC1_HUMAN	Affects Response To Substance	[6]
Low molecular weight phosphotyrosine protein phosphatase (ACP1)	OTJ9CKLU	PPAC_HUMAN	Affects Response To Substance	[6]
G/T mismatch-specific thymine DNA glycosylase (TDG)	OTJB0YIH	TDG_HUMAN	Affects Response To Substance	[6]
E3 ubiquitin-protein ligase FANCL (FANCL)	OTJC7QPQ	FANCL_HUMAN	Affects Response To Substance	[6]
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HADH)	OTJDOL20	HCDH_HUMAN	Affects Response To Substance	[6]
Lysophosphatidic acid receptor 1 (LPAR1)	OTJNJQPF	LPAR1_HUMAN	Affects Response To Substance	[6]
Kinesin-like protein KIF15 (KIF15)	OTJRJEXL	KIF15_HUMAN	Affects Response To Substance	[6]
TBC1 domain family member 4 (TBC1D4)	OTK66C40	TBCD4_HUMAN	Affects Response To Substance	[6]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Affects Response To Substance	[6]
Gamma-glutamylcyclotransferase (GGCT)	OTKAICP5	GGCT_HUMAN	Affects Response To Substance	[6]
NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1)	OTKBUQXP	NDUA1_HUMAN	Affects Response To Substance	[6]
Origin recognition complex subunit 6 (ORC6)	OTKQN3KP	ORC6_HUMAN	Affects Response To Substance	[6]
Sideroflexin-1 (SFXN1)	OTL66767	SFXN1_HUMAN	Affects Response To Substance	[6]
Lamina-associated polypeptide 2, isoform alpha (TMPO)	OTL68EL4	LAP2A_HUMAN	Affects Response To Substance	[6]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Increases Response To Substance	[29]
Striatin (STRN)	OTLOZL5I	STRN_HUMAN	Affects Response To Substance	[6]
Succinate--CoA ligase subunit beta, mitochondrial (SUCLA2)	OTMZD4PW	SUCB1_HUMAN	Affects Response To Substance	[6]
Protein downstream neighbor of Son (DONSON)	OTN5HE0W	DONS_HUMAN	Affects Response To Substance	[6]
Cytochrome c oxidase subunit 6B1 (COX6B1)	OTNKXYQI	CX6B1_HUMAN	Affects Response To Substance	[6]
Keratinocyte-associated transmembrane protein 2 (C5ORF15)	OTO126A1	KCT2_HUMAN	Affects Response To Substance	[6]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Affects Response To Substance	[33]
tRNA (TRMT5)	OTOAZBPD	TRM5_HUMAN	Affects Response To Substance	[6]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2)	OTOB6J6R	RIR2_HUMAN	Affects Response To Substance	[6]
Cytochrome c oxidase subunit 5A, mitochondrial (COX5A)	OTP0961M	COX5A_HUMAN	Affects Response To Substance	[6]
DNA fragmentation factor subunit beta (DFFB)	OTPBW5N5	DFFB_HUMAN	Affects Response To Substance	[6]
Interleukin-13 receptor subunit alpha-2 (IL13RA2)	OTPC2G0X	I13R2_HUMAN	Affects Response To Substance	[6]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C)	OTPL0AI1	ABC3C_HUMAN	Affects Response To Substance	[6]
Kazrin (KAZN)	OTPM7BYM	KAZRN_HUMAN	Affects Response To Substance	[6]
G2 and S phase-expressed protein 1 (GTSE1)	OTPP742Z	GTSE1_HUMAN	Affects Response To Substance	[6]
Prostaglandin E synthase 3 (PTGES3)	OTPPQWI0	TEBP_HUMAN	Affects Response To Substance	[6]
Epithelial membrane protein 2 (EMP2)	OTPS2H0L	EMP2_HUMAN	Affects Response To Substance	[6]
Ornithine decarboxylase antizyme 1 (OAZ1)	OTPT0PKZ	OAZ1_HUMAN	Affects Response To Substance	[6]
Sister chromatid cohesion protein DCC1 (DSCC1)	OTPUVLZT	DCC1_HUMAN	Affects Response To Substance	[6]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Affects Response To Substance	[34]
Pentraxin-related protein PTX3 (PTX3)	OTPXHRKU	PTX3_HUMAN	Affects Response To Substance	[6]
Ran-specific GTPase-activating protein (RANBP1)	OTQE226K	RANG_HUMAN	Affects Response To Substance	[6]
Rac GTPase-activating protein 1 (RACGAP1)	OTQE8IEH	RGAP1_HUMAN	Affects Response To Substance	[6]
MAPK/MAK/MRK overlapping kinase (MOK)	OTQK7M9V	MOK_HUMAN	Affects Response To Substance	[6]
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1)	OTQRET2B	S5A1_HUMAN	Affects Response To Substance	[6]
Solute carrier family 22 member 3 (SLC22A3)	OTQYGVXX	S22A3_HUMAN	Affects Response To Substance	[6]
Large ribosomal subunit protein mL63 (MRPL57)	OTRB659E	RT63_HUMAN	Affects Response To Substance	[6]
Dickkopf-related protein 1 (DKK1)	OTRDLUSP	DKK1_HUMAN	Affects Response To Substance	[6]
Olfactory receptor 1I1 (OR1I1)	OTRFD8BH	OR1I1_HUMAN	Affects Response To Substance	[6]
Protein CREG1 (CREG1)	OTRHJ8HK	CREG1_HUMAN	Affects Response To Substance	[6]
Proepiregulin (EREG)	OTRM4NQY	EREG_HUMAN	Affects Response To Substance	[6]
Kinetochore protein NDC80 homolog (NDC80)	OTS7D306	NDC80_HUMAN	Affects Response To Substance	[6]
Latent-transforming growth factor beta-binding protein 2 (LTBP2)	OTS88GSD	LTBP2_HUMAN	Affects Response To Substance	[6]
Tumor protein D53 (TPD52L1)	OTSA6U0I	TPD53_HUMAN	Affects Response To Substance	[6]
Inhibin beta A chain (INHBA)	OTSP64PQ	INHBA_HUMAN	Affects Response To Substance	[6]
Leucine-rich repeat-containing protein 1 (LRRC1)	OTSVD30Q	LRRC1_HUMAN	Affects Response To Substance	[6]
NADH dehydrogenase flavoprotein 2, mitochondrial (NDUFV2)	OTSZF7D6	NDUV2_HUMAN	Affects Response To Substance	[6]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Affects Response To Substance	[6]
Rho GTPase-activating protein SYDE1 (SYDE1)	OTTIAF4D	SYDE1_HUMAN	Affects Response To Substance	[6]
Isocitrate dehydrogenase , mitochondrial (IDH2)	OTTQA4PB	IDHP_HUMAN	Affects Response To Substance	[6]
Importin subunit alpha-1 (KPNA2)	OTU7FOE6	IMA1_HUMAN	Affects Response To Substance	[6]
General transcription factor II-I (GTF2I)	OTUYL1TQ	GTF2I_HUMAN	Affects Response To Substance	[6]
Integrin beta-1-binding protein 1 (ITGB1BP1)	OTVQFNGS	ITBP1_HUMAN	Affects Response To Substance	[6]
Transcription factor IIIA (GTF3A)	OTVROUVQ	TF3A_HUMAN	Affects Response To Substance	[6]
ATP-binding cassette sub-family A member 2 (ABCA2)	OTVSYK0X	ABCA2_HUMAN	Decreases Response To Substance	[31]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Affects Response To Substance	[6]
Serine/threonine-protein kinase 26 (STK26)	OTW4QE0D	STK26_HUMAN	Affects Response To Substance	[6]
Homer protein homolog 1 (HOMER1)	OTWFD3SI	HOME1_HUMAN	Affects Response To Substance	[6]
Acyl-coenzyme A thioesterase 13 (ACOT13)	OTWRUST1	ACO13_HUMAN	Affects Response To Substance	[6]
Divergent protein kinase domain 1A (DIPK1A)	OTWS5V2I	DIK1A_HUMAN	Affects Response To Substance	[6]
Urokinase-type plasminogen activator (PLAU)	OTX0QGKK	UROK_HUMAN	Affects Response To Substance	[6]
Hematopoietic lineage cell-specific protein (HCLS1)	OTX7WGYN	HCLS1_HUMAN	Affects Response To Substance	[6]
Nucleotide triphosphate diphosphatase NUDT15 (NUDT15)	OTX8SZOT	NUD15_HUMAN	Affects Response To Substance	[6]
NADH dehydrogenase 1 alpha subcomplex subunit 3 (NDUFA3)	OTXL10N9	NDUA3_HUMAN	Affects Response To Substance	[6]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1)	OTXNGZCG	MD2L1_HUMAN	Affects Response To Substance	[6]
Kinesin-like protein KIF20A (KIF20A)	OTXOQHE0	KI20A_HUMAN	Affects Response To Substance	[6]
Condensin complex subunit 2 (NCAPH)	OTXOS97C	CND2_HUMAN	Affects Response To Substance	[6]
Kinesin-like protein KIF23 (KIF23)	OTY850JC	KIF23_HUMAN	Affects Response To Substance	[6]
Protein FAN (NSMAF)	OTYNVZ23	FAN_HUMAN	Affects Response To Substance	[6]
Proteasome subunit beta type-1 (PSMB1)	OTYRFBAH	PSB1_HUMAN	Affects Response To Substance	[6]
Acetyl-CoA acetyltransferase, cytosolic (ACAT2)	OTZ092ZJ	THIC_HUMAN	Affects Response To Substance	[6]
G-protein coupled receptor 176 (GPR176)	OTZ8PL9B	GP176_HUMAN	Affects Response To Substance	[6]
Tissue factor pathway inhibitor 2 (TFPI2)	OTZCRWOR	TFPI2_HUMAN	Affects Response To Substance	[6]
C-X-C motif chemokine 5 (CXCL5)	OTZOUPCA	CXCL5_HUMAN	Affects Response To Substance	[6]

Indication(s) of Lapatinib

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[4]
Gastroesophageal junction adenocarcinoma	2B71	Approved	[5]
Melanoma	2C30	Approved	[5]

Lapatinib Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Inhibitor	[36]
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[36]
Eukaryotic elongation factor 2 kinase (eEF-2K)	TT1QFLA	EF2K_HUMAN	Inhibitor	[37]

Lapatinib Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[38]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[39]

Lapatinib Interacts with 4 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[40]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[41]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[40]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[41]

Lapatinib Interacts with 36 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Decreases Activity	[42]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[43]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Expression	[44]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[44]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[44]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Increases Activity	[44]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[45]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Decreases Activity	[42]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[46]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[47]
DNA topoisomerase 1 (TOP1)	OT51O0CF	TOP1_HUMAN	Decreases Expression	[48]
DNA topoisomerase 2-alpha (TOP2A)	OT6LPS08	TOP2A_HUMAN	Decreases Expression	[48]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[48]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[46]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Decreases Activity	[49]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Decreases Activity	[50]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Increases Secretion	[51]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[42]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Activity	[46]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Activity	[46]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Activity	[42]
DNA replication licensing factor MCM7 (MCM7)	OT6FXC6K	MCM7_HUMAN	Decreases Expression	[46]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[48]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[42]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[48]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[48]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[47]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[52]
GTPase KRas (KRAS)	OT78QCN8	RASK_HUMAN	Decreases Response To Substance	[53]
HLA class II histocompatibility antigen, DQ alpha 1 chain (HLA-DQA1)	OTC6GISG	DQA1_HUMAN	Increases ADR	[54]
Zinc finger protein SNAI1 (SNAI1)	OTDPYAMC	SNAI1_HUMAN	Decreases Response To Substance	[55]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Increases Metabolism	[48]
Cytochrome P450 3A7 (CYP3A7)	OTTCDHHM	CP3A7_HUMAN	Increases Metabolism	[48]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Response To Substance	[55]
Tenascin-X (TNXB)	OTVBWAV5	TENX_HUMAN	Increases ADR	[54]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Increases ADR	[54]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCLJZO7	CAOV3	Investigative	[1]
Adenocarcinoma	DCUE4LH	NCIH2122	Investigative	[1]
Adenocarcinoma	DCKF985	NCIH23	Investigative	[1]
Adenocarcinoma	DCWQDGU	COLO320DM	Investigative	[1]
Adenocarcinoma	DC5JFX6	DLD1	Investigative	[1]
Ewing sarcoma-peripheral primitive neuroectodermal tumour	DCKQTB3	ES2	Investigative	[1]
Malignant melanoma	DCPIKUP	RPMI7951	Investigative	[1]
Malignant melanoma	DCVDV8K	SKMEL30	Investigative	[1]
Malignant melanoma	DCL4NTC	UACC62	Investigative	[1]
Ovarian endometrioid adenocarcinoma	DCX5WYO	A2780	Investigative	[1]
Ovarian serous cystadenocarcinoma	DCYLRUU	SK-OV-3	Investigative	[1]
Prostate carcinoma	DC4EWUY	VCAP	Investigative	[1]
Breast and ovarian cancer syndrome	DC1H99O	UWB1289	Investigative	[56]
Breast and ovarian cancer syndrome	DCNYV13	UWB1289+BRCA1	Investigative	[56]
Breast carcinoma	DC93T4L	KPL1	Investigative	[56]
Breast carcinoma	DC87NOS	OCUBM	Investigative	[56]
Rectal adenocarcinoma	DCX6XU7	SW837	Investigative	[56]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Vinblastine FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6851).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
• [5] Lapatinib FDA Label
• [6] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [7] Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20.
• [8] Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci. 2004 Mar 9;6(1):E8.
• [9] Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
• [10] Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
• [11] Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
• [12] MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
• [13] Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
• [14] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [15] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [16] Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 2005 Sep;272(18):4725-40.
• [17] MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer. 2001 May 18;84(10):1405-11. doi: 10.1054/bjoc.2001.1776.
• [18] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [19] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [20] Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
• [21] PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
• [22] Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem. 1998 Dec 18;273(51):34639-45. doi: 10.1074/jbc.273.51.34639.
• [23] Cytoskeletal architecture differentially controls post-transcriptional processing of IL-6 and IL-8 mRNA in airway epithelial-like cells. Exp Cell Res. 2006 May 15;312(9):1496-506. doi: 10.1016/j.yexcr.2006.01.010. Epub 2006 Feb 24.
• [24] Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunol Immunother. 2003 Mar;52(3):185-93. doi: 10.1007/s00262-002-0357-4. Epub 2003 Feb 7.
• [25] Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
• [26] Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL. Mol Cell Biochem. 2001 Sep;225(1-):7-20. doi: 10.1023/a:1012203110027.
• [27] Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT. J Cell Physiol. 2007 Jan;210(1):246-56. doi: 10.1002/jcp.20861.
• [28] Amyloid beta protein-related death-inducing protein induces G2/M arrest: Implications for neurodegeneration in Alzheimer's disease. J Neurosci Res. 2007 Aug 1;85(10):2262-71. doi: 10.1002/jnr.21351.
• [29] E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006 Jul 15;66(14):7253-60. doi: 10.1158/0008-5472.CAN-05-3725.
• [30] CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
• [31] Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2006 Aug;5(8):1986-94.
• [32] Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci. 2007 May;64(9):1137-44. doi: 10.1007/s00018-007-6510-7.
• [33] Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999 Apr 1;18(13):2241-51. doi: 10.1038/sj.onc.1202526.
• [34] c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol. 2008;29(5):287-303. doi: 10.1159/000156706. Epub 2008 Sep 19.
• [35] UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3. Chem Biol Interact. 2019 Sep 1;310:108745. doi: 10.1016/j.cbi.2019.108745. Epub 2019 Jul 9.
• [36] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [37] Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813.
• [38] Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
• [39] The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
• [40] Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
• [41] Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
• [42] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [43] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [44] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [45] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [46] CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
• [47] Effects of lapatinib on cell proliferation and apoptosis in NB4 cells. Oncol Lett. 2018 Jan;15(1):235-242. doi: 10.3892/ol.2017.7342. Epub 2017 Nov 3.
• [48] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [49] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [50] Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.
• [51] Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
• [52] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [53] The K-Ras effector p38 MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. J Biol Chem. 2017 Sep 8;292(36):15070-15079. doi: 10.1074/jbc.M117.779488. Epub 2017 Jul 24.
• [54] HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011 Feb 20;29(6):667-73. doi: 10.1200/JCO.2010.31.3197. Epub 2011 Jan 18.
• [55] Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. Int J Biochem Cell Biol. 2016 Feb;71:12-23. doi: 10.1016/j.biocel.2015.11.014. Epub 2015 Nov 28.
• [56] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.